Company profilePharmaceutical#269 of 1,318 in Pakistan1 DRAP alert

CIBEX (PRIVATE) LIMITED

Pharmaceutical company · 69 brands · 78 molecules

Ranked #67 of 178 companies in Antiinflammatory And Antirheumatic Products

69 registered products 35 pharmaceutical brands 78 distinct molecules 1 DRAP alert

Company overview

69
registered products
35
pharmaceutical brands
78
distinct molecules
11
therapeutic classes
1
DRAP alerts

CIBEX (PRIVATE) LIMITED is a pharmaceutical manufacturer registered with the Drug Regulatory Authority of Pakistan, holding 69 product registrations across 78 distinct molecules. Its portfolio is concentrated in Antiinflammatory And Antirheumatic Products and Drugs For Peptic Ulcer And Gastro-Oesophageal Reflux Disease (Gord). DRAP has issued 1 alert involving its products.

Compiled from the DRAP registry, DRAP approved prices and DRAP alerts, with observed retail from DVAGO and Servaid. Data as of 2026-07-30.

Products by CIBEX

41 products matched in our catalogue — each with its observed price and DRAP approved ceiling.

Antiinflammatory And Antirheumatic Products 2

Price ceiling age

DRAP sets a maximum price per registration and revises it only on application. In a market with high inflation, an old ceiling erodes margin in real terms.

39
ceilings with an approval date
0
not revised in 2+ years
2026
oldest approval year
202639

Top molecules by brand count

Azithromycin4 brands
Rifampicin4 brands
Levofloxacin3 brands
Ibuprofen3 brands
Paracetamol3 brands
Linezolid3 brands
Diclofenac2 brands

Therapeutic classes

Antiinflammatory And Antirheumatic Products · 4Drugs For Peptic Ulcer And Gastro-Oesophageal Reflux Disease (Gord) · 2Lipid Modifying Agents · 1Tetracyclines · 1Drugs For Constipation · 1Urologicals, Antiinfectives · 1Cough Expectorant · 1Vitamin B Complex Plain & With Vitamin C · 1Antihistamines For Systemic Use · 1Nasal Preparations · 1Quinolone Antibacterials · 1

Price band (DRAP official ceilings)

Registered products priced by source
DRAP-official56 products · Rs 34.99 – Rs 5,246.92
DVAGO2 products · Rs 133 – Rs 182.4
Median across source: Rs 345.98

Regulatory record

1 alert in the DRAP feed we track.

Recall Alert: Recall of Substandard “Famobex Suspension” Batch No. 5330, Manufactured by M
2025-06-24

Competitive set

Companies whose registered portfolio overlaps most with this one.

BIO LABS (PVT) LTD.31 shared molecules
NEUTRO PHARMA (PVT) LTD.30 shared molecules
SEARLE PAKISTAN (PVT.) LTD.29 shared molecules
IRZA PHARMA (PVT) LTD.27 shared molecules
HIGH - Q INTERNATIONAL26 shared molecules

Portfolio whitespace

Molecules the closest competitors have registered and this company has not — the starting point for a launch shortlist.

BIO LABS (PVT) LTD. holds 125 molecules not in this portfolio
000 I.UAmlodipineAprepitantAremetherArtesunateAscorbic Acid
NEUTRO PHARMA (PVT) LTD. holds 112 molecules not in this portfolio
AcetylcysteineAcyclovirAlbendazoleAmikacinAnastrazoleAnastrozole
SEARLE PAKISTAN (PVT.) LTD. holds 223 molecules not in this portfolio
AcetazolamideAdalimumabAlprazolamAmilorideAminophyllineAmitriptyline

Get the full profile for CIBEX

This page is a summary. The full company brief adds every registration with its approved ceiling and approval date, per-molecule competitive position, price positioning against the category, and a launch shortlist built from the whitespace above.

Request this brief See what’s included

Company data as of 2026-07-30. Brand and molecule counts from the DRAP registry and observed retail sources.

For medicine intelligence and professional reference only. Not medical advice.